WOBURN, Mass., April 29 /PRNewswire/ -- Repromedix has launched a panel of two new advanced tests for male infertility that, taken together, provide the clearest indication of a sperm's ability to successfully achieve pregnancy and live birth. Taken together these tests go well beyond information provided by traditional sperm testing, such as count and motility.
Repromedix' Advanced Male Reproductive Potential Panel includes the Sperm DNA Fragmentation Assay (SDFA(TM)) and Sperm DNA Decondensation (SDD(TM)) Test. Results suggesting low to poor fertility potential indicate that a couple has little or no chance of conceiving a child naturally or through assisted reproductive technologies (ART) such as In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI). When conducted at the outset of infertility treatment, these tests could eliminate emotional and financial costs leading a couple to pursue other options, such as sperm donation or adoption.
Male infertility is a significant medical problem, with 40% of all infertility ascribed entirely or in part to male factors and an additional 20% unexplained. Data suggests that approximately 10-20% of the couples screened will have abnormal results from either the SDD test, the SDFA test, or both, and are unlikely to benefit from expensive, painful, and time consuming IVF procedures without treatment.
Launch of the highly complex male infertility tests comes just one month after Repromedix received $1.6 million in expansion investment capital from Brook Venture Partners LLC and the Massachusetts Business Development Corp in Wakefield, Mass.
Repromedix is the leading national laboratory specializing in advanced reproductive testing. By taking an interdisciplinary approach to clinical testing, the company helps doctors find solutions to their most difficult cases of female and male infertility, recurrent pregnancy loss, and high-risk pregnancy. The Woburn, Mass. based company was founded in 1994 by CEO Craig Sockol. It serves physicians and their patients throughout the United States and Canada.
CONTACT: Julie Dennehy for Repromedix, +1-508-533-8311